Haema 2012; 3(2): 175-182
by Ioanna Sakellari
Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
Author: admin
Treatment options for patients with high risk Myelodysplastic syndromes
Haema 2012; 3(2): 158-174
by Vassiliki Pappa
Assistant Professor of Hematology, Medical School University of Athens, Second Department of Internal Medicine and Research Institute, Attikon University General Hospital, Athens, Greece
Continue reading “Treatment options for patients with high risk Myelodysplastic syndromes”
Therapeutic options for low-risk Myelodysplastic Syndromes patients excluding supportive care and growth factors
Haema 2012; 3(2): 151-157
by Athanasios Galanopoulos
Hematologist, General Hospital «G. Gennimatas», Athens
The role of hematopoietic growth factors in the treatment of patients with Myelodysplastic Syndromes
Haema 2012; 3(2): 143-150
by Maria Psillaki, Katerina Pirovolaki, Helen A. Papadaki
Hematology Clinic, University Hospital, Heraklion, Crete
The role of iron in the pathogenesis of myelodysplastic syndromes (MDS) and results of iron chelation treatment in patients with MDS
Haema 2012; 3(2): 134-142
by Alexandra Kourakli–Simeonidou, Argiris Simeonidis
Hematology Division, Dept of Internal Medicine, University of Patras Medical School, Patras
Myelodysplastic syndromes in children
Haema 2012; 3(2): 125-133
by Alexandros Makis1, Georgia Avgerinou2, Sophia Polychronopoulou2
1Child Health Department, University of Ioannina Medical School, Ioannina, Greece,
2Department of Paediatric Haematology-Oncology, “Aghia Sophia” Children’s Hospital, Athens, Greece
Hypoplastic and fibrotic myelodysplastic syndromes (MDS)
Haema 2012; 3(2): 117-124
by Nikolaos Giannakoulas, Panagiota Matsouka
Hematology Clinic, University Medical School of Thessalia, General Hospital of Larissa
Continue reading “Hypoplastic and fibrotic myelodysplastic syndromes (MDS)”
Chronic Myelomonocytic Leukemia and other hybrid Myelodysplastic/ myeloproliferative syndromes
Haema 2012; 3(2): 109-116
by Nora Viniou, Panagiotis Diamantopoulos
1st Dept of Internal Medicine, University Medical School of Athens, “Laiko” General Hospital
Therapeutic management of Ph negative Myeloproliferative Neoplasms
Haema 2012; 3(1): 99-108
by Despoina Pantelidou, Maria Papaioannou
Haematology Unit of 1stDepartment of Internal Medicine, AHEPA University Hospital, Thessaloniki
Continue reading “Therapeutic management of Ph negative Myeloproliferative Neoplasms”
Genetic aberrations in Ph negative myeloproliferative neoplasms
Haema 2012; 3(1): 89-98
by Georgios Georgiou, Vasiliki Mpartzi
Research Laboratory of APPK
Continue reading “Genetic aberrations in Ph negative myeloproliferative neoplasms”
Classification and current prognostication of Myeloproliferative Neoplasms
Haema 2012; 3(1): 78-88
by Theodoros Marinakis, George Kanavos, Nikolaos I. Anagnostopoulos
Department of Clinical Hematology, General Hospital of Athens “G. Gennimatas”
Continue reading “Classification and current prognostication of Myeloproliferative Neoplasms”
CML stem cells: the pathway to CML cure?
Haema 2012; 3(1): 65-77
by Maria Dimou, Panayiotis Panayiotidis
1st Department of Propaedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, Greece
Guidelines for the molecular monitoring of patients with CML treated with tyrosine kinase inhibitors
Haema 2012; 3(1): 57-64
by Tassoula Touloumenidou, Apostolia Papalexandri, Kostas Stamatopoulos
Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
The role of Stem Cell Transplantation in CML: For which patients and when
Haema 2012; 3(1): 45-56
by Ifigeneia Tzannou and Ioannis Baltadakis
Department of Hematology and Stem Cell Transplantation Unit, Evaggelismos General Hospital, Athens, Greece
Continue reading “The role of Stem Cell Transplantation in CML: For which patients and when”
Criteria for treatment switch from imatinib to second generation TKIs
Haema 2012; 3(1): 37-44
by Nora-Athina Viniou, Panagiotis Diamantopoulos, Vassiliki Papadopoulou
1st Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, “Laiko” General Hospital, Athens
Continue reading “Criteria for treatment switch from imatinib to second generation TKIs”